Constitutional BRCA1 Epimutations: A Key for Understanding Basal‐Like Breast and High‐Grade Serous Ovarian Cancer
Open Access
- 1 January 2024
- journal article
- review article
- Published by Wiley in Human Mutation
- Vol. 2024 (1) , 7353984
Abstract
Germline pathogenic genetic variants in the BRCA1 and BRCA2 genes are the most frequent causes of familial breast and ovarian cancer. Contrasting BRCA2, epimutations in the BRCA1 gene are frequently detected in tissue from triple‐negative breast (TNBC) and high‐grade serous ovarian cancers (HGSOC). While studies over the last decade have reported BRCA1 epimutations in white blood cells (WBC) from breast and ovarian cancer patients, the potential hazard ratio for incident TNBC and HGSOC was not formally assessed until recently.Conducting a prospective nested case‐control study on women participating in the American Women’s Health Initiative Study, we provided firm evidence that mosaic WBC BRCA1 epimutations, even at allele frequencies < 0.1%, are associated with a significantly increased risk of both incident HGSOC and TNBC > 5 years after WBC collection. In a second study assessing BRCA1 epimutations in WBC and matched tumor samples from TNBC, our results indicated such epimutations to be the underlying cause of around 20% of TNBC, far exceeding the percentage of cases carrying BRCA1 germline pathogenic genetic variants.We detected primary constitutional BRCA1 epimutations in tissues derived from all three germ layers. They occur independently of BRCA1 promoter haplotypes but are present on the same allele in all WBC within affected individuals. Moreover, epimutations are consistently found on the same allele in normal and tumor breast tissue as well as in WBC. This finding, together with BRCA1 epimutations detected in WBC from newborns, strongly indicates an early embryonic event with clonal expansion affecting all germ layers.Future work in the field must lead to an understanding of exactly when and how the BRCA1 epimutations occur and, most importantly, whether primary constitutional epimutations in genes other than BRCA1 may cause an elevated risk of other cancer types.Keywords
Funding Information
- Helse Vest
- Norges Forskningsråd
This publication has 88 references indexed in Scilit:
- Constitutional BRCA1 Methylation and Risk of Incident Triple-Negative Breast Cancer and High-grade Serous Ovarian CancerJAMA Oncology, 2022
- Variation in Breast Cancer Subtype Incidence and Distribution by Race/Ethnicity in the United States From 2010 to 2015JAMA Network Open, 2020
- BRCA1 promoter methylation in peripheral blood is associated with the risk of triple‐negative breast cancerInternational Journal of Cancer, 2019
- Association of Breast and Ovarian Cancers With Predisposition Genes Identified by Large-Scale SequencingJAMA Oncology, 2019
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- Genome‐Wide Measures of Peripheral Blood Dna Methylation and Prostate Cancer Risk in a Prospective Nested Case‐Control StudyThe Prostate, 2017
- Mosaic Epigenetic Inheritance as a Cause of Early-Onset Colorectal CancerJAMA Oncology, 2015
- Methylation patterns in cell‐free plasma DNA reflect removal of the primary tumor and drug treatment of breast cancer patientsInternational Journal of Cancer, 2010
- Promoter methylation patterns of ATM, ATR, BRCA1, BRCA2 and P53 as putative cancer risk modifiers in Jewish BRCA1/BRCA2 mutation carriersBreast Cancer Research and Treatment, 2008
- BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma casesCancer, 2005